 CHARLOTTESVILLE, VA ACCESSWIRE June 15, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW Adial or the Company, a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARDTM pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced the closing on June 11,2020 of its previously announced registered direct offering of 2,820,000 shares of its common stock at a purchase price of 1.85 per share for gross proceeds of 5,217,000 priced at-the-market under Nasdaq rules. In a concurrent private placement, Adial also issued warrants to purchase 2,115,000 shares of common stock, which warrants are immediately exercisable, will expire 5 years from the date of issuance and will have an exercise price of 2.00 per share of common stock. 